Advertisement

Topics

An Expanded Access Program for AM0010 (Pegilodecakin)

2018-06-18 02:03:11 | BioPortfolio

Published on BioPortfolio: 2018-06-18T02:03:11-0400

Clinical Trials [928 Associated Clinical Trials listed on BioPortfolio]

A Study to Evaluate the Pharmacokinetics in Pts After Dosing With AM0010

To evaluate the pharmacokinetics of single and multiple doses of AM0010 in healthy patients

A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Pts After Dosing With AM0010

To evaluate the pharmacokinetics of different dose levels and dose formulations of AM0010 in healthy adult patients

Study of AM0010 With Nivolumab Compared to Nivolumab Alone First-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer

To compare the efficacy of AM0010 in combination with nivolumab versus nivolumab alone in patients with metastatic Non-Small Cell Lung Cancer as measured by objective response rate

Study of AM0010 With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer

To compare the efficacy of AM0010 in combination with pembrolizumab versus pembrolizumab alone in patients with metastatic Non-Small Cell Lung Cancer as measured by objective response rate

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known whether combining melanoma vaccine with interleukin-2 is more effective than vaccine...

PubMed Articles [882 Associated PubMed Articles listed on BioPortfolio]

Thymoquinone induces apoptosis in B16-F10 melanoma cell through inhibition of p-STAT3 and inhibits tumor growth in a murine intracerebral melanoma model.

Prognosis of patients with melanoma brain metastasis is poor despite various chemotherapeutic agents. Researchers focus on finding effective treatment with low risk of toxicity. Thymoquinone (TQ) has ...

Melanoma in situ mimicking a Lichen planus-like keratosis.

The incidence of melanoma has steadily increased over the past three decades. Melanoma in situ (MIS),  defined as melanoma that is limited to the epidermis, contributes to a disproportionately high p...

MALDI MSI of MeLiM melanoma: Searching for differences in protein profiles.

Treatment of advanced cutaneous melanoma remains challenging, and new data on melanoma biology are required. The most widely accepted criteria for the prognostic evaluation of melanoma are histopathol...

Melanoma in US Hispanics: recommended strategies to reduce disparities in outcomes.

Cutaneous melanoma is the most fatal form of skin cancer and presents a considerable public health concern in the United States. Although the age-adjusted incidence of melanoma among US Hispanics is l...

PD-L1 expression in tumor infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients.

Programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade immunotherapy has shown notable therapeutic benefit in metastatic melanoma, while the clinical relevance of PD-L1 expression r...

Medical and Biotech [MESH] Definitions

An unpigmented malignant melanoma. It is an anaplastic melanoma consisting of cells derived from melanoblasts but not forming melanin. (Dorland, 27th ed; Stedman, 25th ed)

Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA.

A cellular subtype of malignant melanoma. It is a pigmented lesion composed of melanocytes occurring on sun-exposed skin, usually the face and neck. The melanocytes are commonly multinucleated with a "starburst" appearance. It is considered by many to be the in situ phase of lentigo maligna melanoma.

Found in large amounts in the plasma and urine of patients with malignant melanoma. It is therefore used in the diagnosis of melanoma and for the detection of postoperative metastases. Cysteinyldopa is believed to be formed by the rapid enzymatic hydrolysis of 5-S-glutathionedopa found in melanin-producing cells.

A melanosome-specific protein that plays a role in the expression, stability, trafficking, and processing of GP100 MELANOMA ANTIGEN, which is critical to the formation of Stage II MELANOSOMES. The protein is used as an antigen marker for MELANOMA cells.

More From BioPortfolio on "An Expanded Access Program for AM0010 (Pegilodecakin)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial